Witnessing the stock’s movement on the chart, on Thursday, Bristol-Myers Squibb Co (NYSE: BMY) set off with pace as it heaved 0.06% to $47.03, before settling in for the price of $47.00 at the close. Taking a more long-term approach, BMY posted a 52-week range of $39.35-$63.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 15.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 496.84%. This publicly-traded company’s shares outstanding now amounts to $2.04 billion, simultaneously with a float of $2.03 billion. The organization now has a market capitalization sitting at $95.71 billion. At the time of writing, stock’s 50-day Moving Average stood at $52.53, while the 200-day Moving Average is $54.16.
Bristol-Myers Squibb Co (BMY) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – General industry. Bristol-Myers Squibb Co’s current insider ownership accounts for 0.10%, in contrast to 81.47% institutional ownership. According to the most recent insider trade that took place on May 09 ’25, this organization’s President, RayzeBio Org. sold 97 shares at the rate of 38.01, making the entire transaction reach 3,702 in total value, affecting insider ownership by 0. Preceding that transaction, on Apr 25 ’25, Company’s EVP,Chief Med.Offr.,Drug Dev. bought 4,250 for 47.58, making the whole transaction’s value amount to 202,215. This particular insider is now the holder of 83,513 in total.
Bristol-Myers Squibb Co (BMY) Earnings and Revenue Records
Bristol-Myers Squibb Co’s EPS increase for this current 12-month fiscal period is 496.84% and is forecasted to reach 6.07 in the upcoming year.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Let’s observe the current performance indicators for Bristol-Myers Squibb Co (BMY). It’s Quick Ratio in the last reported quarter now stands at 1.17. The Stock has managed to achieve an average true range (ATR) of 1.51. Alongside those numbers, its PE Ratio stands at $17.66, and its Beta score is 0.39. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.01. Similarly, its price to free cash flow for trailing twelve months is now 7.31.
In the same vein, BMY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.66, a figure that is expected to reach 1.68 in the next quarter, and analysts are predicting that it will be 6.07 at the market close of one year from today.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
Going through the that latest performance of [Bristol-Myers Squibb Co, BMY]. Its last 5-days volume of 11.56 million was inferior to the volume of 13.47 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 74.74% While, its Average True Range was 1.40.
Raw Stochastic average of Bristol-Myers Squibb Co (BMY) in the period of the previous 100 days is set at 15.68%, which indicates a major fall in contrast to 45.91% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.43% that was higher than 31.73% volatility it exhibited in the past 100-days period.
